The Ischemia Modified Albumin In Diagnosing Ischemic New Events

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

1250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-09-30

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the utility of Ischemia Modified Albumin (IMA) for risk stratification in patients presenting with chest discomfort and possible ischemic heart disease, and to evaluate the diagnostic and prognostic implication for IMA for major adverse cardiac events.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

NCT00310544

Myocardial Infarction

COMPLETED PHASE2

Myocardial Oedema in Acute Myocardial Infarction (AMI)

NCT00987259

Myocardial Infarction

COMPLETED

Study of Coronary Artery Computed Tomography to Diagnose Emergency Chest Pain

NCT00273832

Chest Pain Angina Pectoris Myocardial Infarction

COMPLETED PHASE2

Study for Evaluation of Newly Onset Chest Pain and Rapid Diagnosis of Myocardial Necrosis

NCT03227159

Acute Myocardial Infarction

COMPLETED

Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging

NCT03265535

Coronary Artery Disease Myocardial Ischemia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Disease, Ischemic Ischemia, Myocardial Ischemic Heart Disease Unstable Angina

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>=21 years
* Presentation within two hours of relief of most recent episode of chest pain or presence of on-going symptoms suggestive of coronary ischemia, which should be at least 10 minutes in duration.
* Patients being evaluated for suspected ischemic signs and or symptoms (chest pain) at the time of presentation according to routine standard of care institutional chest pain protocol/pathway.

Exclusion Criteria

* Administration of thrombolytic medication prior to first (presentation) blood draw
* Acute coronary syndrome (ACS) secondary to supply/demand inequity (i.e. known anemia, tachycardia, - defined as HR greater than 150 bpm, known sepsis, hypotension, defined as blood pressure \< 90 mmHg).
* Established diagnosis of liver cirrhosis
* Other acute ischemic sources (ongoing severe claudication, mesenteric ischemia, acute TIA/CVA)
* Renal failure requiring dialysis
* Greater than 2 hours from relief of the most recent episode of chest pain or signs and symptoms suggestive of coronary ischemia.
* Chest pain following traumatic injury to the chest
* Evidence for sever systemic infection, manifesting as fever (temperature \>100 degrees) and systolic blood pressure \<100 mmHg
* Patients unwilling or unable to provide written consent, without available next of kin
* Cocaine-related chest pain
* Pregnancy
* Known diagnosis of active malignancy
* Acute Bowel Ischemia
* Severe peripheral vascular disease
* Acute brain ischemia

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No